FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMicrobix Biosystems Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MBXBF
Microbix Biosystems Inc. Stock AnalysisComprehensive stock analysis for Microbix Biosystems Inc. (MBXBF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMBXBF
MBXBF
Microbix Biosystems Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MBXBF
  1. Home
  2. Stocks
  3. Microbix Biosystems Inc.

Microbix Biosystems Inc.

🇺🇸MBXBF•OTC

Microbix Biosystems Inc.

🇺🇸MBXBF•OTC
Market cap
$21.93M

Your view on MBXBF

Mkt Cap
$21.93M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Microbix Biosystems Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Cameron L. Groome
Headquarters
265 Watline Avenue, Mississauga, ON, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Cameron L. Groome
Headquarters
265 Watline Avenue, Mississauga, ON, CA
Description

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally.

It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.

The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.

It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Microbix Biosystems Inc.. Starting points for Microbix Biosystems Inc.: EPS -$0.04, beta 0.38 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Microbix Biosystems Inc.. Microbix Biosystems Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Microbix Biosystems Inc.. Trailing twelve-month EPS for Microbix Biosystems Inc. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterSep 2026This yearYear to Sep 2026Next yearYear to Sep 2027
Average estimateCAD 0.00−CAD 0.01CAD 0.01
Lowest estimateCAD 0.00−CAD 0.01CAD 0.01
Highest estimateCAD 0.00−CAD 0.01CAD 0.01
Number of analysts011
A year ago−CAD 0.01−CAD 0.02—
Growth vs a year ago+100.0%+38.1%—

Revenue estimates

TotalThis quarterSep 2026This yearYear to Sep 2026Next yearYear to Sep 2027
Average estimateCAD 4.42MCAD 16.16MCAD 20.02M
Lowest estimateCAD 4.42MCAD 16.16MCAD 20.02M
Highest estimateCAD 4.42MCAD 16.16MCAD 20.02M
Number of analysts111
A year agoCAD 3.75MCAD 18.61M—
Growth vs a year ago+17.7%−13.2%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Microbix Biosystems Inc.. Microbix Biosystems Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MBXBF18 companies
Compare MBXBF with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AHGIFAlternate Health Corp.HealthcareMedical - Healthcare Information Services$7,788
BBIXFBonus BioGroup Ltd.HealthcareBiotechnology$157.7M
CLYYFCelyad Oncology S.A.HealthcareBiotechnology$6.7M
DTCFFDefence Therapeutics Inc.HealthcareBiotechnology$22.9M
ELVAFEvolva Holding S.A.Financial ServicesShell Companies$7.9M
PVCTProvectus Biopharmaceuticals, Inc.HealthcareBiotechnology$18.7M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NTLAIntellia Therapeutics, Inc.HealthcareNASDAQ$1.4B
NTRBNutriband Inc.HealthcareNASDAQ$59.8M
NTRBWNutriband Inc.HealthcareNASDAQ$76.8M
NTRRNeutra Corp.HealthcareOTC$291,790
NURPFNeuren Pharmaceuticals LimitedHealthcareOTC$1.1B
NUVBNuvation Bio Inc.HealthcareNYSE$1.3B
NUZ.AXNeurizon Therapeutics LimitedHealthcareASX—
NVAXNovavax, Inc.HealthcareNASDAQ$1.2B
NVCTNuvectis Pharma, Inc.HealthcareNASDAQ$666.8M
NWBONorthwest Biotherapeutics, Inc.HealthcareOTC$359.4M
NWPHFNewron Pharmaceuticals S.p.A.HealthcareOTC$239.5M
NXTCNextCure, Inc.HealthcareNASDAQ$29.5M
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Microbix Biosystems Inc.. Coverage tracks Microbix Biosystems Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Microbix Biosystems Inc.

MBXBF AnalysisFair
Past
3
Growth
1
Health
4
Profit
1
Value
1